anonymous
Guest
anonymous
Guest
I am surprised there is nothing yet posted about the fate of this division. So, let’s hear it. The UTI med is slated for submission in 2025. Trelegy will be taking a huge financial hit with the $35 cap coming. Any thoughts on what this sales force has in store? Layoffs coming? Q3? Anyone have intel on what the UTI med chances are for approval?